Rigel Pharmaceuticals appoints Mark J. Frohlich to board of directors

RIGEL PHARMACEUTICALS INC

Appointed March 6, 2025; joins class of directors with term expiring at 2027 annual meeting.
Will serve on Corporate Governance, Health Care Compliance Oversight and Nominating Committee and Scientific and Clinical Trial Advisory Committee.
Received initial option grant for 12,000 shares; annual retainer $50,000 plus $10,000 per committee.
Board determined Frohlich is independent under SEC and Nasdaq standards; no familial relationships.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark J. Frohlich

Director

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2025-03-06
Filed: March 10, 2025, 7:59 PM ET

On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark J. Frohlich was appointed as Director at RIGEL PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.

View on SEC.gov

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-25-022224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.